The Native Antigen Company human coronavirus antigens and antibodies

Thursday, 12 May, 2022 | Supplied by: BioNovus Life Sciences


The Native Antigen Company develops and manufactures high-quality recombinant antigens and antibodies as well as offering a range of services for the diagnostic and biopharmaceutical industries. The company’s VirtuE mammalian expression system has been developed for the purpose of producing native-like proteins, which are being widely adopted by in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital.

There are six different coronaviruses that can infect humans and cause illness. These comprise the four common coronaviruses — 229E and NL63 (alpha coronaviruses), and OC43 and HKU1 (beta coronaviruses) — and two other coronaviruses, MERS-CoV and SARS-CoV, both of which can cause severe illness and remain a significant public health concern. Following the declaration of SARS-CoV-2 pandemic by the WHO in March 2020, Native Antigen has rapidly expanded its range of SARS-CoV-2 recombinant antigens and antibodies.

To support the investigation of SARS-CoV-2 variants, the company offers a growing range of mutant Spike antigens. Expressed through the VirtuE mammalian expression system, the antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.

Online: www.bionovuslifesciences.com.au
Phone: 02 9484 0931
Related Products

Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)

Cayman Chemical's Bio-Active Lipid I Screening Library consists of 13 plates and contains...

Echelon Biosciences ionisable lipids

Echelon Biosciences' ionisable lipids are the key components of lipid nanoparticles (LNPs)...

BioStatus CyTRAK Orange fluorescent dye

BioStatus's CyTRAK Orange is a novel fluorescent dye that preferentially stains the nucleus...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd